# BIAF — BioAffinity Technologies Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BIAF  
**Sources:** 19  
**Published:** 2026-10-12  
**Canonical:** https://app.k3vl4r.com/research/deep-research-biaf-bioaffinity-technologies-inc-catalysts-narrative-ri-7181

---

## Context

bioAffinity Technologies, Inc. (NASDAQ: BIAF, with BIAFW for warrants) is a micro-cap biotech based in San Antonio developing the non-invasive CyPath® Lung diagnostic test for early-stage lung cancer, marketed as a Laboratory Developed Test through its subsidiary Precision Pathology Laboratory Services [[2]](https://finance.yahoo.com/markets/stocks/articles/bioaffinity-technologies-announces-1-15-120000474.html)[[19]](https://finance.yahoo.com/markets/stocks/articles/bioaffinity-technologies-announces-1-15-120000474.html). As a small company, its share price and trading have been volatile, and at various points it traded below the level requiring intervention (see below). The following reflects sources dated roughly July–October 2026.

## Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-biaf-bioaffinity-technologies-inc-catalysts-narrative-ri-7181 (free to sign up)._
